193 related articles for article (PubMed ID: 23647539)
1. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
2. Substrate inhibition of 17β-HSD1 in living cells and regulation of 17β-HSD7 by 17β-HSD1 knockdown.
Han H; Thériault JF; Chen G; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():36-45. PubMed ID: 28554725
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
5. 3D-structure of human estrogenic 17beta-HSD1: binding with various steroids.
Lin SX; Han Q; Azzi A; Zhu DW; Gangloff A; Campbell RL
J Steroid Biochem Mol Biol; 1999; 69(1-6):425-9. PubMed ID: 10419021
[TBL] [Abstract][Full Text] [Related]
6. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.
Zhang CY; Wang WQ; Chen J; Lin SX
J Steroid Biochem Mol Biol; 2015 Jun; 150():24-34. PubMed ID: 25257817
[TBL] [Abstract][Full Text] [Related]
7. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
9. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of human 17β-hydroxysteroid dehydrogenase type 1 complexed with estrone and NADP
Li T; Stephen P; Zhu DW; Shi R; Lin SX
FEBS J; 2019 Jun; 286(11):2155-2166. PubMed ID: 30768851
[TBL] [Abstract][Full Text] [Related]
11. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Aka JA; Calvo EL; Lin SX
Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
[TBL] [Abstract][Full Text] [Related]
12. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
14. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
[TBL] [Abstract][Full Text] [Related]
15. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
16. Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1).
He W; Gauri M; Li T; Wang R; Lin SX
Gene; 2016 Aug; 588(1):54-61. PubMed ID: 27102893
[TBL] [Abstract][Full Text] [Related]
17. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
[TBL] [Abstract][Full Text] [Related]
18. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
19. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase.
Gangloff A; Shi R; Nahoum V; Lin SX
FASEB J; 2003 Feb; 17(2):274-6. PubMed ID: 12490543
[TBL] [Abstract][Full Text] [Related]
20. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
Poirier D
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]